Company profile: Arima Genomics
1.1 - Company Overview
Company description
- Provider of 3D genomics solutions including Arima-HiC to capture chromatin organization, Arima Capture-HiC for high-resolution targeted chromatin conformation, and Arima-HiChIP for protein-DNA interaction analysis; plus genome assembly of reference-quality, chromosome-spanning assemblies, and cancer genomics and human health offerings delivering insights into disease mechanisms, biomarkers, and therapeutic targets.
Products and services
- Arima Capture-HiC: High-resolution, targeted product that captures specific genomic regions for detailed chromatin conformation exploration, enabling precise characterization of chosen loci and their structural arrangements
- Arima-HiChIP: Immunoprecipitation-coupled, integrated assay that combines chromatin immunoprecipitation with HiC for detailed analysis of protein–DNA interactions
- Arima-HiC: Proximity ligation-based method that captures the organizational structure of chromatin in three dimensions, constructing 3D mappings of chromatin organization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arima Genomics
Miromatrix
HQ: United States
Website
- Description: Provider of fully biological human organs and organ-derived products to address the transplant shortage, using patented perfusion decellularization/recellularization technology, plus PAH therapy and patient support via Remodulin (IV/SC), ASSIST, Archways for inhaled/oral treprostinil, and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miromatrix company profile →
Dewpoint Therapeutics
HQ: United States
Website
- Description: Provider of condensate-modifying drugs and an AI-powered drug discovery platform focused on biomolecular condensates. Offers therapies targeting TDP-43 for ALS and neurodegenerative diseases and beta catenin for cancers such as colorectal cancer. Engages in partnerships with pharmaceutical companies to develop drugs for cardiovascular diseases, insulin resistance, and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dewpoint Therapeutics company profile →
Univercells
HQ: Belgium
Website
- Description: Provider of end-to-end, high-density, low-cost biomanufacturing solutions, including the NevoLine vaccine platform (incl. inactivated polio vaccine), scale-X single-use bioreactors, Exothera viral vector CDMO, custom bioproduction hubs with preclinical to commercial GMP capabilities, turnkey advisory for local site design/operation/regulatory compliance, and Ntensify RNA production in mobile labs; engineered to cut investments >75% and cost of goods up to 90%.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Univercells company profile →
Intelligent BioSystems
HQ: United States
Website
- Description: Provider of an advanced DNA sequencing system, focused on commercialization. Founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju, the company builds on Dr. Gordon’s prior role founding Intelligent Automation Systems, which delivered key instrumentation solutions that helped complete the Human Genome Project.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intelligent BioSystems company profile →
Applied StemCell
HQ: United States
Website
- Description: Provider of animal and cell line models as tools for drug discovery and diagnostics, leveraging proprietary TARGATT gene modification technology to create site-specific knock-in mouse, rat, and human cell line models quickly and efficiently for the pharmaceutical and academic community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied StemCell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arima Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arima Genomics
2.2 - Growth funds investing in similar companies to Arima Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arima Genomics
4.2 - Public trading comparable groups for Arima Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →